Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required. Results: All patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26–64.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival.

Efficacy of residual site radiation therapy (ISRT) in patients with primary mediastinal lymphoma with Deauville Score 4 following R-CHT: results of a retrospective mono institutional study / Facondo, Giuseppe; Serio, Mattia; Vullo, Gianluca; Bianchi, MARIA PAOLA; Pelliccia, Sabrina; DI ROCCO, Alice; Lanzolla, Tiziana; Valeriani, Maurizio; DI NAPOLI, Arianna; Tafuri, Agostino; Martelli, Maurizio; Osti, Mattia Falchetto; DE SANCTIS, Vitaliana. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:11(2023), pp. -1. [10.3390/jcm12113777]

Efficacy of residual site radiation therapy (ISRT) in patients with primary mediastinal lymphoma with Deauville Score 4 following R-CHT: results of a retrospective mono institutional study

Giuseppe Facondo
;
Mattia Serio;Gianluca Vullo;Maria Paola Bianchi;Sabrina Pelliccia;Alice Di Rocco;Tiziana Lanzolla;Arianna Di Napoli;Agostino Tafuri;Maurizio Martelli;Mattia Falchetto Osti;Vitaliana De Sanctis
2023

Abstract

Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in terms of progression-free survival (PFS) and overall survival (OS) in patients with primary mediastinal lymphoma (PMBCL) with Deauville Score 4 (DS 4) following rituximab and chemotherapy treatment (R-ICHT). Methods: Thirty-one patients with PMBCL were recruited. After completion of R-ICHT, patients were staged with 18F-fluorodeoxyglucose positron-emission tomography, showing DS 4, and were treated with adjuvant RSRT. The chosen techniques for RT delivery were intensity-modulated radiation therapy (IMRT) or three-dimensional conformal RT (3D-CRT). Most patients underwent the first one using cone-beam computed tomography (CBCT). All patients were evaluated every 3 months for the first 2 years and every 6 months afterwards for a period of at least 5 years, with clinical and radiological procedures as required. Results: All patients received RSRT with a dose of 30 Gy in 15 fractions. The median follow-up time of 52.7 months (IQR: 26–64.1 months). The 5-year OS rate was 100%. The 2-year and 5-year PFS rates were 96.7% and 92.5%, respectively. Patients with relapsed disease had been treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (auto-SCT). Conclusion: RSRT in patients with PMBCL treated with ICHT and DS 4 did not impact unfavorably on patient survival.
2023
lymphoma; primary mediastinal lymphoma; radiotherapy; residual site radiation therapy
01 Pubblicazione su rivista::01a Articolo in rivista
Efficacy of residual site radiation therapy (ISRT) in patients with primary mediastinal lymphoma with Deauville Score 4 following R-CHT: results of a retrospective mono institutional study / Facondo, Giuseppe; Serio, Mattia; Vullo, Gianluca; Bianchi, MARIA PAOLA; Pelliccia, Sabrina; DI ROCCO, Alice; Lanzolla, Tiziana; Valeriani, Maurizio; DI NAPOLI, Arianna; Tafuri, Agostino; Martelli, Maurizio; Osti, Mattia Falchetto; DE SANCTIS, Vitaliana. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 12:11(2023), pp. -1. [10.3390/jcm12113777]
File allegati a questo prodotto
File Dimensione Formato  
Facondo_Efficacy_2023.pdf

accesso aperto

Note: articolo in rivista
Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1681373
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact